WebBackground: Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u-HCC), changes in hepatic function during therapy have yet to be reported. Aim: This retrospective clinical study aimed to elucidate early responses to Atez/Bev. Methods: From September 2024 to April 2024, … WebCancer Reports. 出版年份:2024 年文章数:暂无数据 投稿命中率:暂无数据. 出版周期:Monthly 自引率:暂无数据 审稿周期:暂无数据. 前往期刊查询. 期刊讨论 中国SCI论 …
CANCER IMMUNOLOGY IMMUNOTHERAPY_影响因子(IF)_中科 …
WebCancer Rep (Hoboken). 2024 May 2;e1399. doi: 10.1002/cnr2.1399. ... Cancer Reports published by Wiley Periodicals LLC. Grant support Merck Ltd., Taipei, Taiwan; an affiliate of Merck KGaA, Darmstadt, Germany, as part of an alliance between Merck KGaA and Pfizer. WebOct 11, 2024 · 之前后台有好几个小伙伴想要小编整理下个案报道(Case report)比较好发的期刊,今天小编给大家推荐的是发表大量个案研究,审稿较快的期刊。. 1. Medicine. 医学专业期刊,发表医学相关的内容,包括个案报道、研究论文、综述等。. Medicine是发表个案报 … edging sidewalk with string trimmer
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular ...
WebThe Cancer Reports Latest Journal's Impact IF 2024-2024 is 3.488. More Cancer Reports Journal's Impact Trend, Prediction, Ranking & Key Factor Analysis are all in Acadmeic Accelerator. WebCANCER CANCER Editorial Office 3380 Chastain Meadows Parkway, Suite 200 Kennesaw, GA 30144 USA Phone: 404-327-6411 Fax: 404-417-8016 E-mail: [email protected] Production Contact Information. CANCER Production John Wiley & Sons, Inc. 111 River Street Hoboken, NJ 07030-5774 USA Fax: 201-748-8852 E-mail: [email … WebJun 29, 2024 · 2024 年 6 月 29 日,科睿唯安终于正式发布了 2024 年度 SCI 期刊影响因子。. 肿瘤领域 top10 名单不变,唯一的变化是 Nature Reviews Clinical Oncology 涨了将近 20 分,从 2024 年的第 4 位上升至第 2 位。. 我们来看看今年肿瘤领域影响因子前 10 位的期刊。. 1. CA-A CANCER JOURNAL ... edging stencils